The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine

Anesthesia and Analgesia

Volumn 91, Issue 5, 2000, Pages 1207-1212

  Jokinen, Mika J ^a,b   Ahonen, Jouni ^a   Neuvonen, Pertti J ^a   Olkkola, Klaus T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; ERYTHROMYCIN; FLUVOXAMINE; ROPIVACAINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG URINE LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033762586     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/00000539-200011000-00030     Document Type: Article

References (21)

1. Ropivacaine
2. Metabolism and excretion of ropivacaine in humans
3. Metabolism of the local anesthetic, ropivacaine, by human hepatic cytochrome P450
4. Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes
5. Overview of the pharmacokinetics of fluvoxamine
6. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
7. Pharmacokinetic drug interactions of macrolides
8. A potentially hazardous interaction between erythromycin and midazolam
9. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors
10. Determination of ropivacaine and [2 H 3]ropivacaine in biological samples by gas chromatography with nitrogen-phosphorus detection or mass spectrometry
11. Lack of metabolic racemisation of ropivacaine, determined by liquid chromatography using a chiral AGP column
12. Determination of erythromycin base and 2-acetylerythromycin in human plasma using highperformance liquid chromatography with electrochemical detection
13. Sensitive one-step extraction procedure for column liquid chromatographic determination of fluvoxamine in human and rat plasma
14. Disposition kinetics of ropivacaine in humans
15. Effect of age and gender on the activity of human hepatic CYP3A
16. Drug interactions with tobacco smoking: An update
17. Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers
18. Pharmacokinetics and analgesic effect of ropivacaine during continuous epidural infusion for postoperative pain relief
19. Pharmacokinetics of ropivacaine and bupivacaine during 21 hours of continuous epidural infusion in healthy male volunteers
20. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine